Rita Leporati - Dissemin

Language
Login

All papers authored by Rita Leporati

This paper was not found in any repository, but could be made available legally by the author.

2024 Rita Leporati

ORCID

, Daniela Miliziano, Teresa Beninato

ORCID

ORCID

, Sara Manglaviti

ORCID

, Marta Brambilla

ORCID

, Mario Occhipinti

ORCID

, Arsela Prelaj, Claudia Proto, Giuseppe Lo Russo

Response to lorlatinib rechallenge in a case of ALK-rearranged metastatic NSCLC with a resistance mutation to second generation TKIs

Upload

This paper was not found in any repository, but could be made available legally by the author.

Rita Leporati

ORCID

, Teresa Beninato, Sara Iadecola, Chiara Andreon, Fabio Murianni, Melissa Balsamo, Antonia Martinetti, Benedetta Lombardi Stocchetti, Laura Mazzeo, Sara Manglaviti, Mario Occhipinti, Marta Brambilla, Arsela Prelaj, Claudia Proto, Rosalba Miceli and 5 other authors

Abstract 3702: Dissecting circulating tumor cells phenotype in a cohort of locally advanced non-small cell lung cancer patients undergoing neoadjuvant chemotherapy

Upload

This paper was not found in any repository, but could be made available legally by the author.

Igor Gomez-Randulfe, Rita Leporati

ORCID

, Brinda Gupta, Stephen Liu

ORCID

, Raffaele Califano

ORCID

Recent advances and future strategies in first-line treatment of ES-SCLC

Upload

This paper was not found in any repository, but could be made available legally by the author.

Teresa Beninato, Giuseppe Lo Russo, Rita Leporati

ORCID

, Luca Roz, Giulia Bertolini

Circulating tumor cells in lung cancer: Integrating stemness and heterogeneity to improve clinical utility

Upload

This paper was not found in any repository, but could be made available legally by the author.

2023 Sara Manglaviti, Marta Bini, Giulia Apollonio, Ernesto Zecca, Giulia Galli, Sabina Sangaletti, Alice Labianca, Elisa Sottotetti, Marta Brambilla, Mario Occhipinti, Claudia Proto, Arsela Prelaj, Diego Signorelli, Alessandro De Toma, Giuseppe Viscardi and 12 other authors

High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors

Upload

This paper was not found in any repository, but could be made available legally by the author.

Marta Brambilla, Teresa Beninato

ORCID

, Anna Piemontese, Laura Mazzeo, Chiara Carlotta Pircher, Sara Manglaviti, Paolo Ambrosini, Diego Signorelli, Daniele Lorenzini, Arsela Prelaj, Roberto Ferrara, Claudia Proto, Giuseppe Lo Russo, Elio Gregory Pizzutilo, Monica Ganzinelli and 12 other authors

Exploring the Role of Immunotherapy-Based Treatments for Advanced Non–Small-Cell Lung Cancer With Novel Driver Alterations

Upload

This paper was not found in any repository, but could be made available legally by the author.

Emma Zattarin, Ida Taglialatela, Riccardo Lobefaro, Rita Leporati

ORCID

, Giovanni Fucà, Francesca Ligorio, Caterina Sposetti, Leonardo Provenzano, Jacopo Azzollini, Andrea Vingiani, Cristina Ferraris, Gabriele Martelli, Siranoush Manoukian, Giancarlo Pruneri, Filippo de Braud and 1 other authors

Breast cancers arising in subjects with germline BRCA1 or BRCA2 mutations: Different biological and clinical entities with potentially diverse therapeutic opportunities

Upload

This paper is made freely available by the publisher.

Francesca Corti, Maria Pia Brizzi, Vito Amoroso, Dario Giuffrida, Francesco Panzuto, Davide Campana, Natalie Prinzi, Massimo Milione, Tommaso Cascella, Carlo Spreafico, Giovanni Randon, Simone Oldani, Rita Leporati

ORCID

, Giulia Scotto, Iolanda Pulice and 6 other authors

Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial

Download from doi.org

This paper is made freely available by the publisher.

Giuseppe Lo Russo, Arsela Prelaj

ORCID

, James Dolezal, Teresa Beninato, Luca Agnelli, Tiziana Triulzi, Alessandra Fabbri, Daniele Lorenzini, Roberto Ferrara, Marta Brambilla, Mario Occhipinti, Laura Mazzeo, Leonardo Provenzano, Andrea Spagnoletti, Giuseppe Viscardi and 21 other authors

PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis

Download from doi.org

This paper is made freely available by the publisher.

Emma Zattarin, Daniele Presti, Luigi Mariani

ORCID

, Caterina Sposetti

ORCID

, Rita Leporati

ORCID

, Alice Menichetti, Chiara Corti

ORCID

, Chiara Benvenuti, Giovanni Fucà

ORCID

, Riccardo Lobefaro, Francesca Ligorio, Leonardo Provenzano, Andrea Vingiani, Marta Del Vecchio, Gaia Griguolo

ORCID

and 24 other authors

Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors

Download from doi.org

This paper was not found in any repository, but could be made available legally by the author.

Riccardo Lobefaro

ORCID

, Luigi Mariani, Giorgia Peverelli, Francesca Ligorio, Giovanni Fucà, Alessandro Rametta, Emma Zattarin, Rita Leporati

ORCID

, Daniele Presti, Beatrice Cantarelli, Catherine Depretto, Andrea Vingiani, Siranoush Manoukian, Gianfranco Scaperrotta, Giulia V. Bianchi and 4 other authors

Efficacy and Safety of First-line Carboplatin-paclitaxel and Carboplatin-gemcitabine in Patients With Advanced Triple-negative Breast Cancer: A Monocentric, Retrospective Comparison

Upload

This paper is made freely available by the publisher.

Emma Zattarin

ORCID

, Luigi Mariani, Alice Menichetti, Rita Leporati

ORCID

, Leonardo Provenzano, Francesca Ligorio, Giovanni Fucà, Riccardo Lobefaro, Luca Lalli, Andrea Vingiani, Federico Nichetti, Gaia Griguolo, Marianna Sirico, Ottavia Bernocchi, Antonio Marra and 17 other authors

Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors

Download from doi.org

This paper is made freely available by the publisher.

2022 Luca Cantini, Francesco Paoloni, Federica Pecci, Francesco Spagnolo, Sophie Aerts, Alice Indini, Sara Fancelli, Fabrizio Citarella, Mattia Garutti, Maria Chiara Sergi, Raffaele Giusti, Anna Maria Di Giacomo, Antonello Veccia, Diego Luigi Cortinovis, Rita Leporati

ORCID

and 5 other authors

Extended interval dosing in patients with cancer receiving immune checkpoint inhibitors: Safety analysis from the EDICI study.

Download from doi.org

This paper is made freely available by the publisher.

2021 Carla Ripamonti, Rita Leporati

ORCID

, Giulia De Feo, Patricia Di Pede, Luisa Toffolatti, Mauro Guglielmo, Domenico La Carpia, Guido Miccinesi, Francesca Chiesi

Italian version of the Edmonton Symptom Assessment System (ESAS)–Total Care (TC): development and psychometric validation in patients undergoing cancer treatment or follow-up

Download from link.springer.com

This paper is made freely available by the publisher.

Francesca Ligorio

ORCID

, Giovanni Fucà

ORCID

, Emma Zattarin, Riccardo Lobefaro, Luca Zambelli, Rita Leporati

ORCID

, Carmen Rea, Gabriella Mariani, Giulia V. Bianchi, Giuseppe Capri, Filippo de Braud, Claudio Vernieri

ORCID

The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)—Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab

Download from doi.org

This paper is made freely available by the publisher.

2020 Emma Zattarin, Rita Leporati

ORCID

, Francesca Ligorio, Riccardo Lobefaro

ORCID

, Andrea Vingiani

ORCID

, Giancarlo Pruneri, Claudio Vernieri

ORCID

Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications

Download from doi.org

This paper was not found in any repository, but could be made available legally by the author.

Federico Nichetti

ORCID

, Marta Bini, Margherita Ambrosini

ORCID

, Arianna Ottini, Alessandro Rametta, Rita Leporati

ORCID

, Daniela Polastri, Chiara Pircher, Katia F. Dotti, Filippo de Braud, Laura Ferrari, F. G. M. De Braud

COVID-19 risk for patients undergoing anticancer treatment at the outpatient clinic of the National Cancer Institute of Milan: The COVINT study

Upload

Missing publications? Search for publications with a matching author name.